Novo Nordisk Secures Key China Patent Win for Semaglutide
The Supreme People’s Court of China has delivered a favourable ruling on the intellectual property rights related to the semaglutide compound patent, upholding an earlier decision by the Beijing Intellectual Property Court that confirmed the patent’s validity.
China Patent Win For Semaglutide | 04/01/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy